Lilly Reports Fourth-Quarter and Full-Year 2009 Results

INDIANAPOLIS, Jan. 28 /PRNewswire-FirstCall/ –

– Double-digit revenue growth in Q4 driven by higher volume
– Weaker dollar results in decreased Q4 gross margin
– Company delivers Q4 earnings per share of $.83 (reported) or $.91 (pro forma non-GAAP)
– Full-year 2009 EPS rises to $3.94 (reported) or $4.42 (pro forma non-GAAP)
– Eight products each exceed $1 billion in annual sales
– 2010 EPS guidance range reconfirmed at $4.65 to $4.85

Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2009.

$in millions, except per share data

Fourth Quarter % Full Year %
————– — ——— —
2009 2008 Growth 2009 2008 Growth
—- —- —— —- —- ——
Total Revenue
- Reported $5,934.2 $5,204.4 14% $21,836.0 $20,371.9 7%
Net Income (loss)
- Reported 915.4 (3,629.4) NM 4,328.8 (2,071.9) NM
EPS (Loss per share)
- Reported .83 (3.31) NM 3.94 (1.89) NM

Total Revenue
- Pro forma 5,934.2 5,261.8 13% 21,836.0 20,732.2 5%
Net Income -
Pro forma non-GAAP 999.4 1,116.2 (10)% 4,851.0 4,176.9 16%
EPS – Pro forma
non-GAAP .91 1.02 (11)% 4.42 3.82 16%
=================== ========= ========= === ========= ========= ===

NM – not meaningful

Due to significant strategic actions taken by the company, financial results for 2009 and 2008 are presented on both a reported and a pro forma non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Pro forma non-GAAP results exclude significant items described in the reconciliation tables and also assume the ImClone acquisition was completed January 1, 2008. The pro forma non-GAAP results are presented in order to provide additional insights into the underlying trends in the company’s business. The company’s 2010 financial guidance is also being provided on both a reported and a non-GAAP basis.

“Lilly’s financial results in the fourth quarter completed a year of strong operational performance, highlighted by volume-based revenue gains, improved gross margins and quality earnings growth,” said John C. Lechleiter Ph.D., Lilly’s chairman and chief executive officer. “In 2009, we delivered solid financial results even as we continued to implement a series of actions aimed at speeding innovation to patients and delivering greater value to our customers. In 2010, we are well-positioned, through our new operating structure and development center of excellence, to maximize the value of our portfolio of products worldwide and advance the promising medicines currently in our clinical pipeline.”

Significant Events Over the Last Three Months

– The company restructured the collaboration agreement executed by Bristol-Myers Squibb and ImClone in 2001 to allow for the co-development and co-commercialization of the late-stage oncology molecule necitumumab (IMC-11F8), which is currently in Phase III clinical testing for non-small cell lung cancer. Under the restructured agreement, both companies will share in the cost of developing and potentially commercializing necitumumab in the U.S., Canada and Japan. Lilly maintains exclusive rights to necitumumab in all other markets.
– The company signed a co-promotion agreement with Kowa Pharmaceutical America to commercialize Livalo